{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(62)"],"submitter":["Kripp M"],"pubmed_abstract":["Background
Dermatologic toxicities, especially akne-like skin rash, are the most common side-effects associated with anti-epidermal growth factor receptor (EGFR) therapy. Preemptive treatment with oral tetracyclines is recommended as a standard. Topical prophylactic options have thus far not been compared to tetracyclines. In the current study, we sought to establish an alternative topical treatment.Patients and methods
In this multicentre, randomized, open-label phase II study patients with (K)Ras-wildtype colorectal cancer receiving panitumumab were randomized (1:1) to receive either doxycycline 100 mg b.i.d. (standard arm) or erythromycin ointment 2% followed by doxycycline in case of insufficient activity. The primary endpoint was the percentage of patients developing n"],"journal":["Oncotarget"],"pagination":["105061-105071"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5739620"],"repository":["biostudies-literature"],"pubmed_title":["AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer."],"pmcid":["PMC5739620"],"pubmed_authors":["Stein A","Tessen HW","Hinke A","Prasnikar N","Hannig CV","Kripp M","Hofheinz RD","Neben K","Al-Batran SE","Trarbach T","Vehling-Kaiser U","Quidde J"],"additional_accession":[]},"is_claimable":false,"name":"AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.","description":"Background
Dermatologic toxicities, especially akne-like skin rash, are the most common side-effects associated with anti-epidermal growth factor receptor (EGFR) therapy. Preemptive treatment with oral tetracyclines is recommended as a standard. Topical prophylactic options have thus far not been compared to tetracyclines. In the current study, we sought to establish an alternative topical treatment.Patients and methods
In this multicentre, randomized, open-label phase II study patients with (K)Ras-wildtype colorectal cancer receiving panitumumab were randomized (1:1) to receive either doxycycline 100 mg b.i.d. (standard arm) or erythromycin ointment 2% followed by doxycycline in case of insufficient activity. The primary endpoint was the percentage of patients developing n","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2026-04-12T20:01:19.896Z","creation":"2019-03-27T03:05:30Z"},"accession":"S-EPMC5739620","cross_references":{"pubmed":["29285233"],"doi":["10.18632/oncotarget.21249"]}}